ANTXAN2 Therapeutics, Inc.

Nasdaq an2therapeutics.com


$ 0.95 $ -1.61 (-60.98 %)    

Friday, 09-Aug-2024 15:57:21 EDT
QQQ $ 450.22 $ 2.34 (0.52 %)
DIA $ 395.16 $ 0.63 (0.16 %)
SPY $ 532.81 $ 2.34 (0.44 %)
TLT $ 96.28 $ 0.94 (0.99 %)
GLD $ 224.54 $ 0.55 (0.25 %)
$ 1.03
$ 1.00 x 100
-- x --
-- - --
$ 0.87 - $ 22.22
11,780,452
na
30.66M
$ 1.59
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-14-2024 03-31-2024 10-Q
2 03-29-2024 12-31-2023 10-K
3 11-09-2023 09-30-2023 10-Q
4 08-10-2023 06-30-2023 10-Q
5 05-11-2023 03-31-2023 10-Q
6 03-29-2023 12-31-2022 10-K
7 11-09-2022 09-30-2022 10-Q
8 08-11-2022 06-30-2022 10-Q
9 05-10-2022 03-31-2022 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 lung-disease-focused-an2-therapeutics-lackluster-data-prompts-to-stop-phase-3-study-of-lung-infection-candidate-halves-workforce

AN2 Therapeutics reported topline results from the Phase 2/3 EBO-301 study of epetraborole in treatment-refractory MAC lung dis...

 jmp-securities-maintains-market-outperform-on-an2-therapeutics-lowers-price-target-to-3

JMP Securities analyst Roy Buchanan maintains AN2 Therapeutics (NASDAQ:ANTX) with a Market Outperform and lowers the price t...

 an2-therapeutics-announces-update-on-ebo-301-phase-23-study-evaluating-epetraborole-for-treatment-refractory-mycobacterium-avium-complex-lung-disease-study-to-be-discontinued-following-topline-results

EBO-301 study to be discontinued following topline results from Phase 2 part of the study in treatment-refractory patients with...

 leerink-partners-upgrades-an2-therapeutics-to-outperform

Leerink Partners analyst Joseph Schwartz upgrades AN2 Therapeutics (NASDAQ:ANTX) from Market Perform to Outperform.

 evercore-isi-group-maintains-in-line-on-an2-therapeutics-lowers-price-target-to-2

Evercore ISI Group analyst Liisa Bayko maintains AN2 Therapeutics (NASDAQ:ANTX) with a In-Line and lowers the price target f...

 jmp-securities-upgrades-an2-therapeutics-to-market-outperform-announces-6-price-target

JMP Securities analyst Roy Buchanan upgrades AN2 Therapeutics (NASDAQ:ANTX) from Market Perform to Market Outperform and ann...

 oppenheimer-reiterates-perform-on-an2-therapeuticsto-perform

Oppenheimer analyst Jeff Jones reiterates AN2 Therapeutics (NASDAQ:ANTX) from Perform to Perform.

 an2-therapeutics-q4-eps-057-beats-076-estimate

AN2 Therapeutics (NASDAQ:ANTX) reported quarterly losses of $(0.57) per share which beat the analyst consensus estimate of $(0....

 zoominfo-technologies-to-rally-around-50-here-are-10-top-analyst-forecasts-for-tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

 leerink-partners-downgrades-an2-therapeutics-to-market-perform-lowers-price-target-to-7

Leerink Partners analyst Joseph Schwartz downgrades AN2 Therapeutics (NASDAQ:ANTX) from Outperform to Market Perform and low...

 nasdaq-edges-lower-contextlogic-shares-surge

U.S. stocks traded mostly higher toward the end of trading, while the Nasdaq Composite moved slightly lower on Monday. The Dow...

 why-big-lots-shares-are-trading-lower-by-around-31-here-are-other-stocks-moving-in-mondays-mid-day-session

Shares of Big Lots, Inc. (NYSE: BIG) fell sharply during Monday’s session after the company reported preliminary fourth-quarte...

 evercore-isi-group-downgrades-an2-therapeutics-to-in-line-lowers-price-target-to-7

Evercore ISI Group analyst Liisa Bayko downgrades AN2 Therapeutics (NASDAQ:ANTX) from Outperform to In-Line and lowers the p...

 dow-surges-over-150-points-gilead-sciences-to-acquire-cymabay-therapeutics-for-43b

U.S. stocks traded higher midway through trading, with the Dow Jones index jumping over 150 points on Monday. The Dow traded u...

 oppenheimer-downgrades-an2-therapeutics-to-perform

Oppenheimer analyst Jeff Jones downgrades AN2 Therapeutics (NASDAQ:ANTX) from Outperform to Perform.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION